Valesca Retèl has a PhD degree in Health Economics and an MSc degree in Health Sciences. Currently, she is Head of the Health Technology Assessment (HTA) division at the Netherlands Cancer Institute (NKI-AVL), and endowed professor at the Erasmus University Rotterdam and Erasmus MC, at the Erasmus School of Health Policy and Management. The chair is concerning “Health Technology Assessment in translational research in oncology”. Her research is focused on early Health Technology Assessments concerning a range of applications such as Next Generation Sequencing, Immunotherapy, big data, Image Guided Surgery and cancer survivorship in oncology. Four of these projects are part of a Coverage with Evidence Development program, which she coordinates within the NKI-AVL. Valesca uses mathematical modeling to combine information on besides cost-effectiveness, organizational issues, ethical-legal, and patient related aspects of promising new technologies in early stages of development. In the early stages, broad spectrum scenario drafting is a key element in these early assessments. She currently supervises 8 PhD students. On an international level, she is coordinator of the Health Economics working group of the Organization of European Cancer Institutes (OECI). Additionally, she is co-lead of the research team of the European Fair Pricing Network (EFPN).